The Latest Psychedelics Articles from Streetwise Reports


Healthcare Co. Wants Share of $17.5B Addiction Treatment Industry

Research Report
  ()
One healthcare co. is currently rated a Buy and is making a push for a share of the $17.5-billion addiction treatment industry after a recent study showed its psychedelic-assisted psychotherapy treatment showed a significant decrease in alcohol use, noted a Maxim Group equity research report.
Tags:  PsychedelicsHealthcare Services

Analyst Sees 'Attractive Long-Term Economics' for Healthcare Co.

Research Report
  ()
One healthcare company with upcoming catalysts wants to take a share of the CA$6-billion alcoholism treatment market with its proprietary psychedelic-assisted psychotherapy treatments.
Tags:  PsychedelicsHealthcare Services

Drug Co. to Conduct P1/2a Trial of Psilocybin in Depression

Research Report
  ()
In this trial, slated to commence next quarter, the biopharma will test the efficacy of its version of the psychedelic compound in this mental health indication, noted a ROTH Capital Partners report.
Tags:  Psychedelics

Mental Health Co. Hosts Phase II Trials for LSD, Psilocybin

  ()
This mental health company is pioneering a unique, new treatment for mental health issues such as depression and PTSD in which psychedelics are administered by medical professionals in specialized clinics.
Tags:  Psychedelics

Showing Results: 1 to 4 of 4

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"Experiments showed that PMN's PMN310 has a unique binding profile." ❭
– Douglas Loe, Leede Jones Gable